Avoro Capital Advisors LLC Purchases 650,000 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,150,000 shares of the company's stock after purchasing an additional 650,000 shares during the period. Kymera Therapeutics comprises 2.9% of Avoro Capital Advisors LLC's portfolio, making the stock its 14th biggest holding. Avoro Capital Advisors LLC owned about 7.95% of Kymera Therapeutics worth $207,184,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after buying an additional 270 shares in the last quarter. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics by 95.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Kymera Therapeutics in the fourth quarter valued at about $251,000.

Kymera Therapeutics Trading Down 0.9 %

Shares of NASDAQ:KYMR traded down $0.30 during midday trading on Friday, hitting $33.26. The company had a trading volume of 500,969 shares, compared to its average volume of 555,757. The firm has a fifty day simple moving average of $29.89 and a 200 day simple moving average of $38.61. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -14.21 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 in the last quarter. Company insiders own 15.82% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KYMR. Stephens reiterated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective on the stock. Leerink Partners restated an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, HC Wainwright increased their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.